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Abstract
Since the advent of antiretroviral therapy (ART), morbidity and mortality rates in those infected with human immunodeﬁciency virus
type 1 (HIV-1) have been signiﬁcantly reduced. However, HIV-1 is known to persist in several types of cells and tissues, and will usually
return to pretreatment levels when therapy is stopped, even in those individuals who have been on suppressive ART for a long time.
The discovery of drug sanctuaries and viral reservoirs in the body, in which HIV may persist, has helped to explain why therapeutic erad-
ication of HIV-1 has proved so difﬁcult. Several studies have indicated that the latent reservoir is an archive, composed of a mixture of
wild-type and drug-resistant strains. Archived variants are assumed to remain life-long, thereby precluding the successful recycling of any
drug towards which resistance has arisen. Several studies have underlined the value of pro-viral DNA as an additional source of informa-
tion on the total burden of resistance in an individual. The HIV mutation patterns detected in plasma do not necessarily reﬂect those
found in the cell-associated compartment, and may not be the same as those in different anatomical compartments. Although assessment
of drug resistance in plasma is of direct and immediate importance for treatment, examination of the genotypic pattern of HIV-1 in cellu-
lar compartments might also provide information allowing a more sustainable response to therapy and better disease management.
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Introduction
Although current antiretroviral therapy (ART) is effective
and life-prolonging, it is not curative and does not eradicate
human immunodeﬁciency virus type 1 (HIV-1) infection. It
has been proposed that a major obstacle in HIV-1 eradica-
tion is the ability of the virus to establish a latent infection
within a subpopulation of susceptible cells [1,2]. HIV-1 infec-
tion of activated CD4+ T-cells leads to the production of
virus particles and eventually to cell death from the cyto-
pathic effects of the virus; however, in certain cell popula-
tions, viral replication stops, and such cells represent a
barrier to virus eradication, because of their long half-lives
and because speciﬁcally targeting and purging such reservoirs
is inherently difﬁcult.
The pool of latently infected CD4+ T-cells is established
early in the course of the disease, during primary infection
[2–4]. There are two populations of resting CD4+ T-cells—the
naı¨ve and the memory CD4+ T-cells. The exact contribution
of naı¨ve CD4+ T-cells to the dissemination of the virus and
the establishment of latency is not clear. The relatively short
lifespan of these cells is not consistent with the role of cellular
reservoirs of HIV-1 pro-viral DNA. However, given that the
majority of T-cells in healthy individuals are naı¨ve ones, the fact
that they can be infected with HIV-1 is of crucial importance,
despite their short half-lives. Nevertheless, memory T-cells
make an ideal viral reservoir, because of their long lifespans.
In addition, they are quiescent cells, and their transcriptional
machinery is set in a mode that greatly favours viral latency
with minimal ability to support basal viral transcription. The
infected memory cells can persist for decades before they
receive a stimulating signal that activates the cells, concomi-
tantly inducing virus production [4].
There is no doubt about the presence of latent pro-viral
HIV-1 DNA in the memory CD4+ T-cell populations, and
many authors support the idea that this may be the only
physiologically important, long-term cellular reservoir for
HIV-1, because of the long lifespan of these cells. However,
other investigators have shown that latent HIV-1 pro-viral
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DNA within resting CD4+ T-cells is not the only, and poten-
tially not the major, source of a rebounding virus after treat-
ment ceases. This was discovered when HIV-1 from resting
CD4+ T-cells was compared with the virus that emerged
immediately after therapy ceased, suggesting the presence of
viral reservoirs in cells other than memory CD4+ T-cells [5].
HIV DNA has also been found to persist in cells of the
monocyte–macrophage lineage, including blood-circulating
monocytes [6–8]. Monocytes are known to be released into
the blood from the bone marrow and to circulate in periph-
eral blood for 1–5 days before differentiating into immature
dendritic cells and other tissue macrophages. Depending on
the tissue type, the lifespan of these cells can range from a
few days to several months. Cells of the monocyte–macro-
phage lineage are particularly important in HIV-1 persistence,
because of their ability to cross the blood–brain barrier and
spread HIV-1 infection in the central nervous system (CNS).
In addition to blood cells, some anatomical sites may act
as reservoirs for HIV-1 replication, including the lymph
nodes, brain, genital tract, semen and lungs [9].
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FIG. 1. Main cellular reservoirs of human immunodeﬁciency virus type 1 (HIV-1) drug-resistant variants in the blood compartment. Following
HIV-1 binding to different blood cells, the viral genome is reverse transcribed into DNA. Infection of activated CD4+ T-cells leads to
pronounced production of virions, and eventually to cell death, because of either the cytopathic effect (CPE) of the virus or cytotoxic T lympho-
cytes (CTL) activity. Two populations of resting CD4+ T-cells exist, the naı¨ve and the memory cells. It has been hypothesized that the memory
CD4+ T-cells, which carry the pro-virus, are infected while they are in the process of reverting to the resting state. On activation, these cells
are able to release the drug-resistant archived variants. The contribution of naı¨ve cells to the dissemination of the virus is less clear. In mono-
cytes, HIV-1 replicates at low levels, and infection has no impact on monocyte viability.
CMI Turriziani et al. Resistant HIV variants in cellular reservoirs 1519
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1518–1524
Several authors have demonstrated the presence of cellular
reservoirs harbouring replication-competent viruses in
patients successfully treated with ART [1,10]. The consistent
clinical evidence for a quick rebound in viraemia after therapy
is interrupted is in line with these ﬁndings [11]. Furthermore,
it is known that, in patients failing ART, stopping treatment
or switching antiretroviral drugs results in the resistant virus
in plasma being replaced by wild-type variants. In most of
these individuals, the replacement of the mutant virus by wild
types is rapid, suggesting that it is the result of the reappear-
ance of the archived wild-type virus [11,12].
If the wild-type virus persists in the latent reservoirs for a
long time, then it could be postulated that the drug-resistant
viral variant will also be conserved (Fig. 1). Several studies of
patients in whom ART has been successful but who have a
history of drug resistance have provided evidence of the
dynamic nature of the latent reservoir, and showed that any
viral variant, including any drug-resistant variant, that has
been allowed to replicate for a certain length of time during
infection will enter the reservoir and remain conserved [13–
18]. Once this has occurred, the long-term persistence of
any drug-resistant virus jeopardizes, in a stable manner, the
use of those drugs to which resistance has been developed.
The observation that the pro-viral compartment contains an
archive of heterogeneously mixed wild-type and drug-resis-
tant variants makes this reservoir an ideal substrate for anal-
ysis of the ‘resistance potential’ in a patient.
HIV-1 drug-resistant mutations are actually detected by
analysing plasma viral RNA. However, it is possible that the
HIV-1 pro-viral DNA assay could be used as an alternative
marker, especially when switching therapy in patients with
undetectable viraemia.
HIV-1 Drug-Resistant Variants in Blood
Compartments
In light of the above, there is an increasing body of literature
on the possible utility of assessing drug-resistant mutations in
the pro-virus. Several studies in untreated or failing patients
have emphasized the value of pro-viral DNA as an additional
source of information on the total burden of resistance in an
individual [19–24]. Using direct sequencing, Bon et al. [21]
assessed the prevalence of mutations associated with drug
resistance in cell-free and cell-associated viruses derived
from ART-naı¨ve patients. They reported that the key muta-
tions conferring resistance to reverse transcriptase inhibitors
were detected more frequently in peripheral blood mononu-
clear cells (PBMCs) than in plasma viral RNA, and that major
mutations in the protease region were detectable only in the
cell-associated virus. In conﬁrmation of this, Kabamba-Mukadi
et al. [24] reported that the proportion of mutations in pro-
viral DNA in therapy-naı¨ve patients was signiﬁcantly higher
than that detected with standard RNA genotyping, and that
these mutations persisted for at least 1 year, irrespective of
drug therapy. Against this, other authors have shown that
there is tight concordance of resistance proﬁles in paired
HIV-1 RNA and PBMC HIV-1 DNA in therapy-naı¨ve patients
[25,26].
Several other studies have addressed the level of agree-
ment between mutations associated with drug resistance in
both plasma and PBMCs; however, most of these studies
were performed on samples derived from patients failing
ART who had a history of drug resistance [20,27–29]. These
studies clearly demonstrated that such drug-resistant variants
can easily be found archived in PBMCs, and that the PBMC
compartment does not necessarily reﬂect the plasma com-
partment. This could, indirectly, imply that PBMCs may con-
stitute a reservoir for drug-resistant variants and might
replenish plasma with drug-resistant HIV-1 variants in certain
circumstances. The persistence of drug-resistant mutants in
the reservoir may be particularly important when the circu-
lating virus does not reﬂect the archived population and
when patients undergo more than one salvage treatment.
The importance of performing resistance genotyping on
pro-viral DNA has also been emphasized by Delaugerre et al.
[30]. HIV-1 RNA and HIV-1 DNA samples obtained perina-
tally from a newborn and its mother were analysed, and
resistance mutations were detected early in infant lympho-
cytes. Clonal and longitudinal analyses showed that the pri-
mary acquisition of resistant virus was associated with long-
term persistence in the infant’s cellular reservoir. This article
strongly supports the use of genotype assays, not only in
plasma but also in the newborn’s lymphocytes, because this
would help to show whether resistance was likely to persist,
which has major implications for long-term treatment.
It is recognized that HIV-1 replication in the presence of
drugs is related to viral evolution and selection of resistant
HIV-1 mutants. However, it is less clear whether resistance
to ART can appear after a reasonable degree of viral
suppression has been achieved. Some authors have reported
that when the viraemia is suppressed (to below 50 copies/
mL), resistance does not occur [31], whereas others have
shown that resistance-related mutations can indeed emerge
under such conditions [32]. Diaz et al. [33] conﬁrmed that,
even with minimal viral replication, ART resistance mutations
can be selected and archived in pro-viral DNA.
Although it is plausible that, in the early stage of virologi-
cal failure, detection of emerging resistance mutations is
more sensitive in viral RNA than in pro-viral DNA, the latter
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can be of use in detecting emerging resistance when the viral
load remains at undetectable levels or at levels that preclude
the recovery of HIV-1 RNA though genotyping. Palmisano
et al. [34] both supported and broadened this hypothesis;
they observed that, in a population of HIV-1-positive patients
who were fully responsive to ART, an association existed
between the presence of mutations in pro-viral DNA and
the occurrence of virological failure over the subsequent 2-
year period.
The authors of most studies aimed at analysing the
archived drug-resistant viral variants using PBMCs, and few
data are available on the resistance pattern of viral popula-
tions within individual blood cell types. Some authors com-
pared the drug resistance pattern of HIV-1 from CD4+ T-
cells with viruses harboured in blood monocytes [35,36]. Pot-
ter et al. [35] reported that, in some individuals, distinct viral
populations containing speciﬁc drug-resistant mutations were
present in different blood compartments. In agreement with
these ﬁndings, it has been reported recently that, in patients
failing ART, there is a different distribution of drug-resistant
mutations in CD4+ T-cells, plasma and monocytes [36]. A
number of factors may inﬂuence the compartmentalization of
viral variants in different blood cell types during ART. The
penetration of antiretroviral drugs into different cell types
may be variable, and could alter the selective pressure
responsible for the emergence of drug resistance. It should
also be taken into account that some physiological factors,
such as the expression of some ATP-binding cassette pro-
teins, which can be expressed differently by the various cell
types [37], might affect the uptake of drugs, thus determining
what mutations and variants emerge. It is also well known
that the immune system can exert a strong selective pressure
on viruses, leading to the emergence of viral variants [38,39].
Although recent studies have indicated that HIV-1 replica-
tion occurs in blood monocytes in vivo [40,41], it remains
unclear to what extent HIV-1 can infect and replicate in
blood monocytes. Blood monocytes are able to migrate to
all tissues, such as the lungs, gastrointestinal tract, kidneys,
urogenital tract, primary and secondary lymphoid organs and
CNS. Any viral variants harboured in monocytes could be
carried into these tissues, where they could replicate, thus
contributing, together with the resistant viruses harboured in
CD4+ T-cells, to the persistence of the drug-resistant virus.
HIV-1 Drug-Resistant Variants at other
Anatomical Sites
Although HIV-1 infection leads to systemic disease, several
lines of evidence suggest that HIV-1 compartmentalization
occurs both at the cellular level [1,9] and at anatomical sites,
such as the CNS, male genital tract (MGT), kidneys and lungs
[42–44]. It is recognized that these compartments act as res-
ervoirs for HIV-1 replication and that the virus may replicate
locally after suppression of blood viraemia.
The anatomical barrier may restrict the penetration of
some antiretroviral drugs at some anatomical sites, thus facil-
itating the evolution of drug resistance [45,46]. This dimin-
ished penetration of antiviral medication could result in
lower effective drug levels and in retention of replicating
strains with a wild-type genotype.
A comparison of the genetic diversity and mutational
resistance pattern of the plasma virus and a virus from the
anatomical reservoir revealed that speciﬁc resistance muta-
tions may vary between viruses from different body com-
partments. In a recent study by Canestri et al. [47], it was
demonstrated that, despite successful suppression of plasma
viraemia with ART, HIV-1 may replicate in the cerebrospinal
ﬂuid (CSF), where development of HIV-1 resistance results
in acute or subacute neurological effects. These data conﬁrm
earlier ﬁndings that the development of drug resistance may
vary between the two compartments, and that CSF can act
as a viral reservoir for resistance mutations [45–48]. Fur-
thermore, it should be noted that treatment-resistant viral
strains could be exchanged between the two compartments,
and this could result in treatment failure if a drug-resistant
strain enters the blood from the CSF.
There are interesting data on drug-resistant strains and
anatomical reservoirs from those studies in which the MGT
was analysed. Several comparative studies in blood and
semen have indicated that the MGT may constitute a distinct
compartment in some patients, based on the isolation of
phylogenetically distinct viral quasi-species from semen and
blood [49]. Although ART appears to reduce viral shedding
in semen [50], the rate and pattern of emergence of resis-
tance may differ between the blood compartment and the
MGT [51]. Indeed, it has been reported that, in HIV-1 infec-
tion, the MGT can act either: (i) as a viral compartment with
restricted gene ﬂow and a slower molecular clock [52]; or
(ii) as a viral reservoir with viral persistence [49]; or (iii) as a
drug sanctuary with variable antiretroviral penetration [53].
These characteristics allow for the possible development of
drug resistance and for its long-lived persistence [54]. Smith
et al. [55] demonstrated that drug-resistant HIV-1 persists in
higher proportions in the MGT for longer than it does in
blood. This greater persistence offers a prolonged opportu-
nity for transmission of the drug-resistant virus.
Within the various body compartments, considerable
attention has been dedicated to the rectal mucosa. The sur-
face of the rectal mucosa represents a major route of HIV-1
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infection in both homosexual men and heterosexual part-
ners; hence, the virological aspects of this site have impor-
tant implications for virus transmission. Moreover, the
intestinal mucosa is an anatomical reservoir for HIV-1 [56].
Detectable levels of pro-viral DNA and HIV-1 RNA have
been reported in rectal biopsy specimens of HIV-1-infected
patients, both naı¨ve and during ART. Furthermore, on com-
parison of gut-derived isolates with those from the blood, a
discordant phenotype has been reported [57]. It has been
reported that different levels of drug resistance can be
detected when HIV-1 from rectal biopsy specimens is com-
pared with the blood-derived virus.
The presence of drug-resistant viruses with different resis-
tance proﬁles in body compartments other than blood might
have important therapeutic consequences. It remains to be
determined to what extent these anatomical sites contribute
to the emergence of drug-resistant variants.
Conclusions
Current guidelines recommend the use of antiretroviral
resistance testing of the plasma of drug-naı¨ve patients and of
those failing ART. However, several studies have clearly
demonstrated that drug-resistant variants can easily be found
archived in PBMCs, and that the PBMC compartment does
not necessarily reﬂect the plasma compartment.
In fact, drug-resistant mutations persist at detectable levels
for longer in PBMC DNA than in plasma RNA, because of
the different rates of virus turnover in these two compart-
ments. Indeed, discrepancies between drug-resistant muta-
tions in the virus populations harboured in plasma RNA and
in PBMC DNA have been reported in patients failing therapy
or after treatment interruption, as well as in naı¨ve patients.
From this point of view, routine genotypic plasma analyses
underestimate the presence of resistance relative to what
may be revealed by examination of the virus populations
archived in PBMCs. These observations make the pro-viral
reservoir the ideal substrate for analysis of the total burden
of resistance in an individual. Obviously, it must be empha-
sized that PBMC DNA sequencing cannot be proposed as a
substitute for plasma RNA sequencing.
Several studies suggest that HIV-1 compartmentalization
may occur both at the cellular level and in anatomical sites,
such as the CNS, genital tract, kidneys and lungs. The ana-
tomical barrier may restrict the penetration of antiretroviral
drugs at some anatomical sites, thus facilitating the evolution
of drug resistance. Comparison of the genetic diversity and
mutational resistance pattern of the virus in plasma and in
the anatomical reservoir reveals that speciﬁc drug-resistant
mutations of the virus may vary between different body
compartments.
The different resistance proﬁles of the virus in different
body compartments may have important therapeutic conse-
quences. However, it remains to be determined whether
such differences can contribute to the emergence of drug-
resistant variants during treatment failure.
Although drug-resistant variants may be harboured in dif-
ferent anatomical sites, it is our ﬁrm opinion that PBMC
DNA analysis, in conjunction with the currently recom-
mended plasma RNA analysis, has the potential to increase
the sensitivity of the detection of drug resistance in drug-
naı¨ve patients and in those with a history of ART failure.
Further studies of large HIV-1 populations are warranted to
deﬁne the role of DNA genotyping in both clinical and
research settings.
In conclusion, plasma remains the compartment of choice
for testing of drug resistance. However:
• The concomitant assessment of drug resistance mutations
in both plasma and blood cell compartments might
improve the choice of a new therapeutic regimen.
• In patients responding to ART, in whom plasma HIV-1
RNA cannot be sequenced by commercially available
assays, pro-viral DNA may represent an alternative
means of investigating the genetic evolution of the pre-
dominant viral species in an individual. Prospective studies
should be conducted to verify the predictive capacity of
the HIV-1 DNA genotype and its value in clinical prac-
tice.
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